Trials / Completed
CompletedNCT00002102
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- U.S. Bioscience · Industry
- Sex
- All
- Age
- 1 Day
- Healthy volunteers
- Not accepted
Summary
To provide trimetrexate glucuronate to immunosuppressed patients with Pneumocystis carinii pneumonia (PCP) for whom this investigational compound could provide significant medical benefit.
Detailed description
Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate glucuronate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trimetrexate glucuronate | |
| DRUG | Leucovorin calcium |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002102. Inclusion in this directory is not an endorsement.